Aaron S Rosenberg1, Robin Ruthazer2, Jessica K Paulus2, David M Kent3, Andrew M Evens4, Andreas K Klein4. 1. Division of Hematology/Oncology, Department of Internal Medicine, Tufts University School of Medicine, Boston, MA; Division of Hematology/Oncology, Department of Internal Medicine, Tufts Cancer Center, Boston, MA; Department of Internal Medicine, Tufts Medical Center, Boston, MA. Electronic address: asrosenberg@ucdavis.edu. 2. The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA; Tufts Clinical and Translational Sciences Institute, Tufts University, Boston, MA. 3. Division of Hematology/Oncology, Department of Internal Medicine, Tufts University School of Medicine, Boston, MA; Department of Internal Medicine, Tufts Medical Center, Boston, MA; Tufts Clinical and Translational Sciences Institute, Tufts University, Boston, MA. 4. Division of Hematology/Oncology, Department of Internal Medicine, Tufts University School of Medicine, Boston, MA; Division of Hematology/Oncology, Department of Internal Medicine, Tufts Cancer Center, Boston, MA; Department of Internal Medicine, Tufts Medical Center, Boston, MA.
Abstract
BACKGROUND: Multiple myeloma/plasmacytoma-like posttransplantation lymphoproliferative disorder (PTLD-MM) is a rare complication of solid organ transplantation. Case series have shown variable outcomes, and survival data in the modern era are lacking. PATIENTS AND METHODS: A cohort of 212 PTLD-MM patients was identified in the Scientific Registry of Transplant Recipients between 1999 and 2011. Overall survival (OS) was estimated by the Kaplan-Meier method, and the effects of treatment and patient characteristics on OS were evaluated by Cox proportional hazards models. OS in 185 PTLD-MM patients was compared to 4048 matched controls with multiple myeloma (SEER-MM) derived from Surveillance, Epidemiology, and End Results (SEER) data. RESULTS: Men comprised 71% of patients; extramedullary disease was noted in 58%. Novel therapeutic agents were used in 19% of patients (more commonly during 2007-2011 vs. 1999-2006; P = .01), reduced immunosuppression in 55%, and chemotherapy in 32%. Median OS was 2.4 years and improved in the later time period (adjusted hazard ratio [aHR], 0.64, P = .05). Advanced age, creatinine > 2 g/dL, white race, and use of OKT3 were associated with inferior OS in multivariable analysis. OS of PTLD-MM patients is significantly inferior to SEER-MM patients (aHR, 1.6, P < .001). Improvements in OS over time differed between PTLD-MM and SEER-MM. Median OS of patients diagnosed from 2000 to 2005 was shorter for PTLD-MM than SEER-MM patients (18 vs. 47 months, P < .001). There was no difference among those diagnosed from 2006 to 2010 (44 months vs. median not reached, P = .5; interaction P = .08). CONCLUSION: Age at diagnosis, elevated creatinine, white race, and OKT3 were associated with inferior survival in patients with PTLD-MM. Survival of PTLD-MM is inferior to SEER-MM, although significant improvements in survival have been documented. Copyright Â
BACKGROUND:Multiple myeloma/plasmacytoma-like posttransplantation lymphoproliferative disorder (PTLD-MM) is a rare complication of solid organ transplantation. Case series have shown variable outcomes, and survival data in the modern era are lacking. PATIENTS AND METHODS: A cohort of 212 PTLD-MMpatients was identified in the Scientific Registry of Transplant Recipients between 1999 and 2011. Overall survival (OS) was estimated by the Kaplan-Meier method, and the effects of treatment and patient characteristics on OS were evaluated by Cox proportional hazards models. OS in 185 PTLD-MMpatients was compared to 4048 matched controls with multiple myeloma (SEER-MM) derived from Surveillance, Epidemiology, and End Results (SEER) data. RESULTS:Men comprised 71% of patients; extramedullary disease was noted in 58%. Novel therapeutic agents were used in 19% of patients (more commonly during 2007-2011 vs. 1999-2006; P = .01), reduced immunosuppression in 55%, and chemotherapy in 32%. Median OS was 2.4 years and improved in the later time period (adjusted hazard ratio [aHR], 0.64, P = .05). Advanced age, creatinine > 2 g/dL, white race, and use of OKT3 were associated with inferior OS in multivariable analysis. OS of PTLD-MMpatients is significantly inferior to SEER-MM patients (aHR, 1.6, P < .001). Improvements in OS over time differed between PTLD-MM and SEER-MM. Median OS of patients diagnosed from 2000 to 2005 was shorter for PTLD-MM than SEER-MM patients (18 vs. 47 months, P < .001). There was no difference among those diagnosed from 2006 to 2010 (44 months vs. median not reached, P = .5; interaction P = .08). CONCLUSION: Age at diagnosis, elevated creatinine, white race, and OKT3 were associated with inferior survival in patients with PTLD-MM. Survival of PTLD-MM is inferior to SEER-MM, although significant improvements in survival have been documented. Copyright Â
Authors: Bertram L Kasiske; Aleksandra Kukla; Dolca Thomas; Jennifer Wood Ives; Jon J Snyder; Yang Qiu; Yi Peng; Vikas R Dharnidharka; Ajay K Israni Journal: Am J Kidney Dis Date: 2011-09-17 Impact factor: 8.860
Authors: Stuart M Flechner; Richard Fatica; Medhat Askar; Brian R Stephany; Emilio Poggio; Anna Koo; Stacey Banning; Andres Chiesa-Vottero; Titte Srinivas Journal: Transplantation Date: 2010-12-27 Impact factor: 4.939
Authors: M F Mamzer-Bruneel; C Lomé; E Morelon; V Levy; P Bourquelot; F Jacobs; A Gessain; E Mac Intyre; N Brousse; H Kreis; O Hermine Journal: J Clin Oncol Date: 2000-11-01 Impact factor: 44.544
Authors: Ralf Trappe; Heiner Zimmermann; Susanne Fink; Petra Reinke; Martin Dreyling; Andreas Pascher; Hans Lehmkuhl; Barbara Gärtner; Ioannis Anagnostopoulos; Hanno Riess Journal: Haematologica Date: 2011-07 Impact factor: 9.941
Authors: Scott C Quinlan; Lindsay M Morton; Ruth M Pfeiffer; Lesley A Anderson; Ola Landgren; Joan L Warren; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-04-20 Impact factor: 4.254
Authors: Adam J Waxman; Pamela J Mink; Susan S Devesa; William F Anderson; Brendan M Weiss; Sigurdur Y Kristinsson; Katherine A McGlynn; Ola Landgren Journal: Blood Date: 2010-09-07 Impact factor: 22.113
Authors: Jason S Knight; Alexander Tsodikov; Diane M Cibrik; Charles W Ross; Mark S Kaminski; Douglas W Blayney Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544